Terms: = Lung cancer AND JAK1, ENSG00000162434, P23458, JTK3, JAK1B, JAK1A, 3716 AND Treatment
52 results:
1. EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation.
Qin Z; Yue M; Tang S; Wu F; Sun H; Li Y; Zhang Y; Izumi H; Huang H; Wang W; Xue Y; Tong X; Mori S; Taki T; Goto K; Jin Y; Li F; Li FM; Gao Y; Fang Z; Fang Y; Hu L; Yan X; Xu G; Chen H; Kobayashi SS; Ventura A; Wong KK; Zhu X; Chen L; Ren S; Chen LN; Ji H
J Exp Med; 2024 Mar; 221(3):. PubMed ID: 38284990
[TBL] [Abstract] [Full Text] [Related]
2. EPN3 plays oncogenic role in non-small cell lung cancer by activating the jak1/2-STAT3 pathway.
Meng J; Zhang C; Zhu N; Zhang C; Liu M; Han Z; Li Y
Environ Toxicol; 2023 Aug; 38(8):1968-1979. PubMed ID: 37186036
[TBL] [Abstract] [Full Text] [Related]
3. Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways.
Xie Y; Ding J; Gao J; Zhang J; Cen S; Zhou J
Int Immunopharmacol; 2023 May; 118():109993. PubMed ID: 36931170
[TBL] [Abstract] [Full Text] [Related]
4. Effective personalized neoantigen vaccine plus anti-PD-1 in a PD-1 blockade-resistant lung cancer patient.
Gao S; Wang J; Zhu Z; Fang J; Zhao Y; Liu Z; Qin H; Wei Y; Xu H; Dan X; Yang L; Xu Q
Immunotherapy; 2023 Feb; 15(2):57-69. PubMed ID: 36651232
[TBL] [Abstract] [Full Text] [Related]
5. IL-20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer.
He Y; Luo W; Liu Y; Wang Y; Ma C; Wu Q; Tian P; He D; Jia Z; Lv X; Ma YS; Yang H; Xu K; Zhang X; Xiao Y; Zhang P; Liang Y; Fu D; Yao F; Hu G
J Clin Invest; 2022 Oct; 132(20):. PubMed ID: 36006737
[TBL] [Abstract] [Full Text] [Related]
6. Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer.
Liu C; Yang L; Xu H; Zheng S; Wang Z; Wang S; Yang Y; Zhang S; Feng X; Sun N; Wang Y; He J
BMC Med; 2022 May; 20(1):187. PubMed ID: 35550592
[TBL] [Abstract] [Full Text] [Related]
7. Effects of Vitexin, a Natural Flavonoid Glycoside, on the Proliferation, Invasion, and Apoptosis of Human U251 Glioblastoma Cells.
Huang J; Zhou Y; Zhong X; Su F; Xu L
Oxid Med Cell Longev; 2022; 2022():3129155. PubMed ID: 35281458
[TBL] [Abstract] [Full Text] [Related]
8. Determining similarities of COVID-19 - lung cancer drugs and affinity binding mode analysis by graph neural network-based GEFA method.
Budak C; Mençik V; Gider V
J Biomol Struct Dyn; 2023 Feb; 41(2):659-671. PubMed ID: 34877907
[TBL] [Abstract] [Full Text] [Related]
9. Cell Behavior of Non-Small Cell lung cancer Is at EGFR and MicroRNAs Hands.
Hassanein SS; Ibrahim SA; Abdel-Mawgood AL
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830377
[TBL] [Abstract] [Full Text] [Related]
10. A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer.
Padda SK; Reckamp KL; Koczywas M; Neal JW; Kawashima J; Kong S; Huang DB; Kowalski M; Wakelee HA
Cancer Chemother Pharmacol; 2022 Jan; 89(1):105-115. PubMed ID: 34773474
[TBL] [Abstract] [Full Text] [Related]
11. AZD3759 enhances radiation effects in non-small-cell lung cancer by a synergistic blockade of epidermal growth factor receptor and Janus kinase-1.
Zhao R; Yin W; Yu Q; Mao Y; Deng Q; Zhang K; Ma S
Bioengineered; 2022 Jan; 13(1):331-344. PubMed ID: 34738874
[TBL] [Abstract] [Full Text] [Related]
12. GRP78 facilitates M2 macrophage polarization and tumour progression.
Zhang H; Wang SQ; Hang L; Zhang CF; Wang L; Duan CJ; Cheng YD; Wu DK; Chen R
Cell Mol Life Sci; 2021 Dec; 78(23):7709-7732. PubMed ID: 34713304
[TBL] [Abstract] [Full Text] [Related]
13. Machine learning identifies molecular regulators and therapeutics for targeting SARS-CoV2-induced cytokine release.
Chan M; Vijay S; McNevin J; McElrath MJ; Holland EC; Gujral TS
Mol Syst Biol; 2021 Sep; 17(9):e10426. PubMed ID: 34486798
[TBL] [Abstract] [Full Text] [Related]
14. Repurposing Methotrexate in Dampening SARS-CoV2-S1-Mediated IL6 Expression: Lessons Learnt from lung cancer.
Gowda P; Patrick S; Joshi SD; Kumawat RK; Sen E
Inflammation; 2022 Feb; 45(1):172-179. PubMed ID: 34480250
[TBL] [Abstract] [Full Text] [Related]
15. An IFNγ/STAT1/JMJD3 Axis Induces ZEB1 Expression and Promotes Aggressiveness in lung Adenocarcinoma.
Yang J; Wang X; Huang B; Liu R; Xiong H; Ye F; Zeng C; Fu X; Li L
Mol Cancer Res; 2021 Jul; 19(7):1234-1246. PubMed ID: 33771881
[TBL] [Abstract] [Full Text] [Related]
16. Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting.
Wu Z; Tao H; Zhang S; Wang X; Ma J; Li R; Liu Z; Wang J; Cui P; Chen S; Di H; Huang Z; Zheng X; Hu Y
Cancer Immunol Immunother; 2021 Oct; 70(10):2971-2980. PubMed ID: 33740125
[TBL] [Abstract] [Full Text] [Related]
17. IL-10 derived from Hepatocarcinoma cells improves human induced regulatory T cells function via jak1/STAT5 pathway in tumor microenvironment.
Zhang S; Gan X; Qiu J; Ju Z; Gao J; Zhou J; Shi C; Zhu Y; Li Z
Mol Immunol; 2021 May; 133():163-172. PubMed ID: 33667986
[TBL] [Abstract] [Full Text] [Related]
18. Dynamics of genomic and immune responses during primary immunotherapy resistance in mismatch repair-deficient tumors.
Takahashi N; Rajapakse VN; Pongor L; Kumar S; Tlemsani C; Erwin-Cohen R; Young HA; Hewitt S; Wei JS; Khan J; Villarino AV; Trepel JB; Thomas A
Cold Spring Harb Mol Case Stud; 2020 Oct; 6(5):. PubMed ID: 33028646
[TBL] [Abstract] [Full Text] [Related]
19. Inhibition of jak1/2 can overcome EGFR-TKI resistance in human NSCLC.
Kim DM; Kim MJ; Moon JH; Lee EY; Hong JK; Lee S; Koh DI; Ryu YS; Kim SM; Jung SA; Shin JS; Kim J; Park YS; Hong SW; Lee SH; Jung J; Park SS; Kim DY; Kim EH; Jeong HR; Gong JH; Kim J; Chan Kim S; Yu HN; Ki SY; Kim TW; Jin DH
Biochem Biophys Res Commun; 2020 Jun; 527(1):305-310. PubMed ID: 32446385
[TBL] [Abstract] [Full Text] [Related]
20. miR-140-3p inhibits progression of non-small cell lung cancer by targeting Janus kinase 1.
Hu C; Zou Y; Jing LL
J Biosci; 2020; 45():. PubMed ID: 32345774
[TBL] [Abstract] [Full Text] [Related]
[Next]
